Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Jean Kanitakis
Based on 9 articles published since 2008
||||

Between 2008 and 2019, J. Kanitakis wrote the following 9 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline Guidelines of the French Society of Otorhinolaryngology (SFORL), short version. Extension assessment and principles of resection in cutaneous head and neck tumors. 2014

Anonymous4420813 / Durbec, M / Couloigner, V / Tronche, S / Albert, S / Kanitakis, J / Ltaief Boudrigua, A / Malard, O / Maubec, E / Mourrain Langlois, E / Navailles, B / Peuvrel, L / Phulpin, B / Thimonier, J-C / Disant, F / Dolivet, G. ·Service d'ORL, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France. Electronic address: mickael.durbec@chu-lyon.fr. · Société française d'ORL & CCF, 26, rue Lalo, 75116 Paris, France. · Service d'ORL, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France. · Service de dermatologie, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France. · Service de radiologie, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France. · Service d'ORL, Hôtel-Dieu, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France. · Service de dermatologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. · Service de radiologie, Hôtel-Dieu, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France. · Service d'ORL, centre hospitalier de Valence, 179, avenue du Maréchal-Juin, 26000 Valence, France. · Service d'onco-dermatologie, Hôtel-Dieu, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France. · Institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France. · Service d'ORL, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France. · Service d'ORL, département de chirurgie oncologique, institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France. ·Eur Ann Otorhinolaryngol Head Neck Dis · Pubmed #25456243.

ABSTRACT: Cutaneous head and neck tumors mainly comprise malignant melanoma, squamous cell carcinoma, trichoblastic carcinoma, Merkel cell carcinoma, adnexal carcinoma, dermatofibrosarcoma protuberans, sclerodermiform basalioma and angiosarcoma. Adapted management requires an experienced team with good knowledge of the various parameters relating to health status, histology, location and extension: risk factors for aggression, extension assessment, resection margin requirements, indications for specific procedures, such as lateral temporal bone resection, orbital exenteration, resection of the calvarium and meningeal envelopes, neck dissection and muscle resection.

2 Review Critical skin cancer in organ transplant recipients--a dermatopathological view. 2012

Kempf, Werner / Mertz, Kirsten D / Kanitakis, Jean / Hofbauer, Günther F L. ·Kempf and Pfaltz, Histological Diagnostics, University Hospital Zürich, Seminarstrasse 1, Zürich, Switzerland. kempf@kempf-pfaltz.ch ·Curr Probl Dermatol · Pubmed #22377917.

ABSTRACT: Organ transplant recipients (OTR) are at significantly increased risk to develop a wide variety of skin cancers, particularly epithelial skin cancer, Merkel cell carcinoma and Kaposi's sarcoma. In addition, melanoma, skin adnexal neoplasm and cutaneous lymphomas are more common in OTR and may differ in their clinicopathological presentation from tumors in immunocompetent patients. The accuracy of clinical diagnosis of suspected premalignant and malignant skin lesions in OTR is modest. Therefore, histopathological diagnosis is an essential element for the diagnostic workup of skin cancers, and additionally provides important information on prognosis. This review discusses the histopathological aspects of skin cancers in OTR, the impact of dermatopathological analysis on prognosis and understanding of the pathogenesis of these neoplasms.

3 Article Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study. 2017

Fattouh, Kinda / Ducroux, Emilie / Decullier, Evelyne / Kanitakis, Jean / Morelon, Emmanuel / Boissonnat, Pascale / Sebbag, Laurent / Jullien, Denis / Euvrard, Sylvie. ·Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. · Unité de Recherche Clinique, Pôle Information Médicale Evaluation Recherche, Hospices Civils de Lyon, Lyon, France. · EA Santé-Individu-Société, Université Lyon 1, Lyon, France. · Department of Transplantation and Nephrology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. · Department of Transplant Cardiology, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France. ·Transpl Int · Pubmed #28700114.

ABSTRACT: The risk of melanoma in organ transplant recipients (OTR) is increased compared with the general population. This retrospective study registered all cases of post-transplant melanoma in kidney, heart, lung, and liver transplant recipients followed in our specialized post-transplant Dermatology Clinic since 1991. The yearly prevalence of melanoma and skin carcinoma between 2000 and 2015 was computed and compared in this population. Based on another cohort of kidney transplant recipients grafted since 2005, adjusted age- and sex-standardized incidence ratio (SIR) was calculated using a renal transplantation registry. In our overall OTR cohort, between 1991 and 2000, five melanomas occurred in 1800 OTRs (0.28%), whereas between 1991 and 2015, 53 melanomas were diagnosed in 49 of 4510 OTR (1.09%), representing a 3.9-fold increase in prevalence after 2000. Remarkably, the prevalence of nonmelanoma skin cancers remained unchanged over this period. Two deaths related to melanoma were recorded with an overall follow-up of 62 months. In our cohort of 1102 renal transplant recipients, the SIR of melanoma was 4.52. Our data suggest that contrasting with nonmelanoma skin cancer, the risk of post-transplant melanoma has considerably increased over the last decade.

4 Article DeRmpath & Clinic: Regressive melanoma associated with vitiligo-like depigmentation. 2016

Gouillon, Laurie / Villani, Axel-Patrice / Kanitakis, Jean. ·Dermatology Department, Edouard Herriot Hospital, Lyon, France. ·Eur J Dermatol · Pubmed #27528475.

ABSTRACT: -- No abstract --

5 Article Annexin A1 in primary tumors promotes melanoma dissemination. 2014

Boudhraa, Zied / Rondepierre, Fabien / Ouchchane, Lemlih / Kintossou, Roselyne / Trzeciakiewicz, Anna / Franck, Frederic / Kanitakis, Jean / Labeille, Bruno / Joubert-Zakeyh, Juliette / Bouchon, Bernadette / Perrot, Jean Luc / Mansard, Sandrine / Papon, Janine / Dechelotte, Pierre / Chezal, Jean-Michel / Miot-Noirault, Elisabeth / Bonnet, Mathilde / D'Incan, Michel / Degoul, Françoise. ·Clermont-Ferrand Université, Université d'Auvergne, INSERM U990, Imagerie Moléculaire et Thérapie Vectorisée, BP 184, 63000, Clermont-Ferrand, France. ·Clin Exp Metastasis · Pubmed #24997993.

ABSTRACT: Metastatic melanoma is one of the most aggressive forms of skin cancer and has a poor prognosis. We have previously identified Annexin A1 (ANXA1) as a potential murine melanoma-spreading factor that may modulate cell invasion by binding to formyl peptide receptors (FPRs). Here, we report that (1) in a B16Bl6 spontaneous metastasis model, a siRNA-induced decrease in tumoral ANXA1 expression significantly reduced tumoral MMP2 activity and number of lung metastases; (2) in a retrospective study of 61 patients, metastasis-free survival was inversely related to ANXA1 expression levels in primary tumors (HR 3.15 [1.03-9.69], p = 0.045); (3) in human melanoma cell lines, ANXA1 level was positively correlated with in vitro invasion capacity whereas normal melanocytes contained low ANXA1 levels, and (4) the ANXA1 N-terminal peptide ANXA12-26 stimulated MMP2 activity after interaction with FPRs and significantly stimulated the in vitro invasion of melanomas by acting on FPRs. These findings identify ANXA1 as a proinvasive protein in melanoma that holds promise as a potential prognostic marker and therapeutic target.

6 Article BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. 2010

Kanitakis, Jean / Baldassini, Sylvie / Lora, Viviana / Euvrard, Sylvie. ·Department of Dermatology/Laboratory of Dermatopathology, Ed. Herriot Hospital, 69437 Lyon cedex 03, France. jean.kanitakis@univ-lyon1.fr ·Eur J Dermatol · Pubmed #19919912.

ABSTRACT: BRAF is a gene of the RAF family of kinases, frequently mutated in benign and malignant melanocytic tumors (nevi and melanomas). Organ transplant recipients are at high risk for developing various tumors, including melanocytic ones. We studied a group of 129 melanocytic tumors including various subtypes of nevi (n: 114) and melanomas (n: 15) excised from transplant (n: 63) and control (non-immunosuppressed) patients (n: 66) as to BRAF mutation status. Mutation research was performed after extraction of DNA from archival material (paraffin-embedded tissue specimens) by sequence analysis. BRAFV600E accounted for the most prevalent mutation found (94%). Melanocytic tumors from transplant patients had a lower frequency of BRAF mutations than control lesions (45.4% vs 63.5%, p<.05). The explanation for this difference is currently unknown. The possibility exists that in transplant patients, factors linked to immunosuppression (most likely immunosuppressive drugs) induce additional mutations, or activate alternative signaling pathways, which compensates for the lower rate of activating BRAF mutations in tumors developing in these patients.

7 Article In vivo reflectance confocal microscopy of supernumerary nipple and differential diagnosis from melanocytic lesions. 2010

Kanitakis, Jean. ·Department of Dermatology, Ed Herriot Hospital, Lyon, France. jean.kanitakis@univ-lyon1.fr ·J Cutan Pathol · Pubmed #19614734.

ABSTRACT: Supernumerary nipples (SN) represent a developmental abnormality present in 1-6% of the population at large. Although the clinical diagnosis is as a rule easy, this lesion can mimic lentigos and melanocytic nevi, with which it may share some dermatoscopic features. Reflectance confocal microscopy is a new imaging technique that allows in vivo visualization of normal and pathologic skin structures, and is especially useful in the diagnosis of pigmented skin lesions. The reflectance confocal microscopic features of SN are described here, and the potential usefulness of this technique in the differential diagnosis of this lesion from its main clinical mimics is briefly discussed.

8 Article Detection of GD3 ganglioside in primary melanomas depends on histopathologic procedures used for tumor preservation. 2009

Debarbieux, Sébastien / Popa, Iuliana / Thomas, Luc / Kanitakis, Jean / Pirot, Fabrice / Portoukalian, Jacques / Haftek, Marek. ·Laboratoire de Recherche Dermatologique Pavillon R, Hôpital Edouard Herriot, 69437 Lyon 03, France. ·Acta Dermatovenerol Croat · Pubmed #19818222.

ABSTRACT: Gangliosides, cell surface glycosphingolipids, are implicated in diverse biologic functions potentially important for tumor growth. Because expression of the GD3 ganglioside may have an impact on the melanoma malignancy, and therefore on the patient prognosis, we evaluated the feasibility of a retrospective immunohistochemical study of GD3 in paraffin embedded biopsies of primary melanomas. Immunoperoxidase staining of frozen and deparaffinized sections of melanoma lesions with two anti-GD3 antibodies was compared using Dako biotin-streptavidin detection kit. Residual ganglioside content was evaluated in the tissues submitted to routine histopathologic procedures using HPLC. A strong and reproducible staining was obtained with both antibodies on frozen sections of all 17 melanoma samples. However, only KM641 antibody could detect GD3 on deparaffinized sections. Biochemical quantification revealed that the Bouin fixative resulted in degradation of GD3. Additionally, most of GD3 was eluted from the tissue samples during dehydration and re-hydration steps. A subgroup of tumors particularly rich in GD3 could be detected on deparaffinized sections after standard formaldehyde fixation. Clinical evolution of such melanomas can now be compared to the group with low GD3 expression. However, any Bouin-fixed, paraffin-embedded biopsies should be excluded from such a retrospective study.

9 Article Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. 2008

Matin, R N / Mesher, D / Proby, C M / McGregor, J M / Bouwes Bavinck, J N / del Marmol, V / Euvrard, S / Ferrandiz, C / Geusau, A / Hackethal, M / Ho, W L / Hofbauer, G F L / Imko-Walczuk, B / Kanitakis, J / Lally, A / Lear, J T / Lebbe, C / Murphy, G M / Piaserico, S / Seckin, D / Stockfleth, E / Ulrich, C / Wojnarowska, F T / Lin, H Y / Balch, C / Harwood, C A / Anonymous4220608. ·Centre for Cutaneous Research and Department of Dermatology, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK. rnhmatin@hotmail.com ·Am J Transplant · Pubmed #18786232.

ABSTRACT: Organ transplant recipients have a higher incidence of melanoma compared to the general population but the prognosis of this potentially fatal skin cancer in this group of patients has not yet been established. To address this, we undertook a multicenter retrospective analysis to assess outcome for 100 melanomas (91 posttransplant and 9 pretransplant) in 95 individuals. Data were collected in 14 specialist transplant dermatology clinics across Europe belonging to the Skin Care in Organ Transplant Patients, Europe (SCOPE) Network, and compared with age, sex, tumor thickness and ulceration status-matched controls from the American Joint Committee on Cancer (AJCC) melanoma database. Outcome for posttransplant melanoma was similar to that of the general population for T1 and T2 tumors (< or = 2 mm thickness); but was significantly worse for T3 and T4 tumors (> 2 mm thickness); all nine individuals with a pretransplant melanoma survived without disease recurrence following organ transplantation. These data have implications for both cutaneous surveillance in organ transplant recipients and management of transplant-associated melanoma.